Hypothalamic pituitary thyroid (HPT) axis abnormalities and alterations in major depression are reported in literature. The aim of our study was to evaluate the effect of mirtazapine on thyroid hormones after 6 months of therapy in a sample of adult outpatients with Major Depression (MD). 17 adult outpatients (7 men, 10 women) with MD according to DSM-IV criteria, were included in the study. All participants had to have met criteria for a major depressive episode with a score of at least 15 on the Hamilton Depression Rating Scale (HAM-D). Fasting venous blood samples were obtained for determination of serum Thyroid Stimulating Hormone (TSH), Free T3 (FT3) and Free T4 (FT4) concentrations both at baseline and after 6 months oftherapy. HAM-D scores decreased significantly from the first day oftreatment to the end ofthe treatment period (P<0.001) and twelve patients (70.6%) were classified as responders. A significant increase in FT3 concentrations was found between baseline and the end of treatment period (P=O.015) whereas FT4 concentrations decreased (P=0.046). No significant changes were found in TSH levels. Higher FT4 concentrations at baseline predicted higher HAM-D scorers both at baseline and at the end of the treatment period. Furthermore, higher FT3 concentrations at endpoint were found to be predictors of lower HAM-D scores. Long-term treatment with mirtazapine increases FT3 levels and decreases FT4 maybe involving the deiodination process ofT4 into T3.
and noradrenergic antidepressants, but antidepressant treatment has shown controversial effects on HPT (8-9). A potential involvement of brain cytokines and immunomodulatory system is also probable (10-14).
Mirtazapine is a novel antidepressant compound belonging to a new class of noradrenergic and specific serotonergic antidepressants (NaSSA). It enhances both central noradrenergic and serotonergic neurotransmission by directly inhibiting noradrenergic a2-autoreceptors and a2-heteroreceptors (15). It is highly specific, with no effect on monoamine reuptake and a relatively low affinity for dopaminergic receptors and some serotonergic receptor subtypes (16) . Mirtazapine also selectively inhibits specific postsynaptic 5-HT2 and 5-HT3 receptors and histamine-HI receptors (5), and this contributes to its favourable tolerability profile. The antidepressant effect and tolerability of mirtazapine have been well documented (17-18).
Mirtazapine's influence on the endocrine system has been poorly investigated. In the rat hypothalamus, mirtazapine reduced corticotropin-releasing hormone (CRR) release from CRR-containing neurons (19) . Mirtazapine was shown to acutely inhibit cortisol and adrenocorticotropin (ACTH) secretion in healthy subjects (20-21)and attenuates HPAaxishyperactivity in depressed patientspresumablyas a sequelto centraI5-HT2 and/orHI receptor antagonism (22) . Moreover, in healthy male subjects, the stimulatory effects ofreboxetine, a selective noradrenaline reuptake inhibitor, on cortisol, ACTH and prolactin (pRL) via noradrenergic mechanisms are counteracted in part by the a2-blocking properties of mirtazapine and its inhibitory influence on cortisol secretion (23) .Instead, growth hormone (GH) releasedoes not seem to be influencedby mirtazapine (24) .
To date, no studies have investigated the effect of mirtazapine on HPT axis in clinically depressed subjects during long-term therapy. The aim of our study was to evaluate the effect of mirtazapine on thyroid hormones after 6 months oftherapy in a sample ofadult outpatients with major depression (MD).
MATERIALS AND METHODS
17 adult outpatients (7 men, 10 women) with a Major Depressive Episode (single episode or recurrent), according to the Diagnostic and Statistical Manual ofMental Disorders, 4th ed. (DSM-IV) criteria (25) , were included in the study.
Patients were informed about the study and gave their written consent prior to enrolment. Diagnoses were made by psychiatrists with at least 5 years clinical experience and supervised by senior psychiatrists (RMS, FMF), following the Structured Clinical Interview for DSM-IV-Outpatient version (SCID-OP; Italian version) (26) . Their average age was 41.3 ±9.2 years (age range: 27-57 years).
Exclusion criteria were age below 18 years or over 65 years, history of a manic or hypomanic episode, current mania or hypomania, comorbidity with schizophrenia or other psychotic disorders, current drug or alcohol dependence, severe personality disorders, organic mental disorders, serious medical conditions, current pregnancy or breast feeding, treatments with lithium or neuroleptics within 8 months, fluoxetine within 8 weeks, monoamine oxidase inhibitor within 12 weeks or regular psychotropic medication within 8 weeks of starting study medication. Enrolled patients had no thyroid dysfunctions or diseases in their history and had never been treated with thyroid hormone substitution.
All participants had meet the criteria for major depressive episode with a score of at least 15 on the Hamilton Depression Rating Scale, 17-item version (HAM-D) (27) , on the day they were assessed for study inclusion. The HAM-D, a clinically administered instrument, is the most widely used scale for patient selection and follow-up in research studies of treatments for depression. There are two versions of the scale using either 21 or 17 items; the l7-item scale uses the first 17 questions on the full scale. Items are scored from 0 to 4, the higher the score, the more severe the depression. Questions are related to symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels and weight loss.
Mirtazapine was started at 15 mg/day, increased after 1 week to 30 mg/day for all patients, and eventually to 45 mg/day at the end of the second week of treatment (or later if side effects necessitated the delay) depending on clinical response. No other drug was permitted. Mirtazapine response was defmed as a reduction of the HAM-D score of 50% or more as compared with the patient's score at study entry.
Fasting venous blood samples were obtained for determination of thyroid stimulating hormone (TSH), Free T3 (FT3) and Free T4 (FT4) concentrations. The serum TSH concentration was measured by immunoradiometrlc assay (RIA-gnost hTSH, CIS Bio-intemational). The serum FT3 and FT4 concentrations was determined by radioirnrnunoassay (Coat-A-Count Free T4 and Free T3 kits, Diagnostic Products Corp).
Statistical analyses
Descriptive statistics (means and standard deviations as appropriate) and percentages were computed for the study sample on demographic variables and all psychometric scales. The data were checked for deviations from the Gaussian distribution using the Kolmogorov-Smimov test. Results reported in this paper consist primarily of paired Student's t tests to analyze differences between baseline and the end of treatment period among entire sample and unpaired Student's t tests to analyze differences between responders and nonresponders. Chi-square analyses (with the Yates' correction for 2 x 2 tables) were used for categorical variables. Multiple linear regression analysis was performed to assess predictive factors of depression severity (with HAM-D as dependent variable) in study sample. P values equal to or less than 0.05 were considered to be statistically significant. All statistical testing was two-sided. Statistical analyses were performed using SPSS for Windows release 10.0.0 (2000) . All data are expressed as mean ± standard deviation (SD).
RESULTS
In the entire sample, HAM-D scores decreased significantly from first day of treatment to the end of treatment period (P<O.OOl). Twelve patients (70.6%) showed a decrease in HAM-D scores of more than 50% and were considered responders. The remaining 5 patients all showed a response, but the decrease on HAM-D scores was less than 50%. Partial responders had higher HAM-D scores than responders at baseline (respectively 28.8 ± 0.8 vs 25.7 ± 2.7; unpaired t=2.53 df=15 P=0.023). Responders did not differ from non-responders with regard to age and sex. The average mirtazapine dose at the end of the treatment period was 40.9 ± 12.1 (maximum 60 mg/day).
No gender differences were found at baseline on HAM-D scores and thyroid parameters. A significant increase in FT3 concentrations was found after the end of the treatment period with no gender differences (P=0.015) (Tab. I). Furthermore, a significant decrease in FT4 concentrations after the end of the treatment period was found (P=0.046). There was no difference between men and women in any thyroid hormone concentration, after the end of the treatment period. No significant changes were found in thyroid stimulating hormone (TSH) levels between baseline and after the end of treatment period in the entire sample. Comparative analysis of responders and non-responders showed no significant differences in hormone levels both at baseline and after the end of the treatment period.
A multiple linear regression analysis (Tab. II) was conducted to identify whether thyroid parameters both at baseline and after the end of treatment period could be identified as predictive variables ofresponse after the end of the treatment period. As can be seen from Table II , variables explained 58% of the variance (F=16.11 df=6 P<O.OOI). HAM-D score after the end of treatment period was considered as a dependent variable, whereas TSH, FT3, FT4 at baseline and after the end of treatment period were independent variables. Higher FT4 concentrations at 
DISCUSSION
A link between mood disorders and disturbances in thyroid function has often been suggested. The thyrotropin-releasing hormone (TRH) stimulation test has been used extensively to study subtle abnormalities in the hypothalamic-pituitary-thyroid (HPT) axis in depression. A consistent finding has been a blunted TSH response to TRH stimulation in about 25% of depressed patients (28) (29) , particularly those with endogenous symptoms (30) . Increased CSF levels ofTRH have been reported in depression (31) . In addition, up to 10% of depressed patients appear to have an exaggerated TSH response to the TRH stimulation test (32) (33) . It has been suggested that low nocturnal TSH secretion may be a more sensitive measure of HPT axis dysfunction in depression than the TRH stimulation test (23) . Low basal and TRH-stimulated levels ofTSH, as well as low peripheral thyroid hormone levels, while generally considered to be in the "subclinical" hypothyroid range, have been associated with poor response to antidepressant therapies (34) .
In addition, a meta-analysis conducted by Aronson et al. (35) indicates that triiodothyronine (T3) supplementation of antidepressant medication can improve the response rate and can also convert patients with refractory depression to responders. Furthermore, other researchers (36-37) have reported a beneficial effect of thyroid hormone supplementation in patients with rapid-cycling and treatment-refractory bipolar illness. Bauer et al. (38) have speculated that a restricted central hypothyroidism may exist in such patients, in which CNS thyroid function, but not peripheral thyroid function, may be abnormal.
To date, this is the first work that investigates the effect of mirtazapine on thyroid hormones in the long-term treatment of adult outpatients with MD. In our study mirtazapine was well tolerated and no serious adverse effects were reported (39) (40) . We found a significant increase in FT3 concentrations and a decrease in FT4 between baseline and endpoint. This is the main finding of our study and it is partially in contrast with a previous study (41) that evaluated the plasma thyroid index concentration in 21 depressed inpatients treated with amitriptyline and mianserin. During antidepressant treatment the entire patient cohort showed a significant decrease in plasma FT4 concentrations as in our study. However, responders showed a significant drop in FT3 during mianserin treatment, and FT3 levels correlated positively with the improvement in the HAM-D.
Instead, our results are in line with the study of Sagud et al. (42) who evaluated the effects of sertraline treatment on plasma hormone levels in 15 female patients with MD. Treatment with sertraline for 24 weeks increased plasma T3 levels in depressed patients. Also, previous studies found a correlation between T3 concentrations and clinical response to imipramine (43) , amytriptiline and fluoxetine (3). We also found that higher FT3 concentrations at endpoint were predictors oflower HAM-D scores.
The data of this study are of interest because T3 is more commonly used to increase antidepressant responses (44) , suggesting that elevation ofT3 levels in the circulation and presumably in the brain may have a beneficial effect on depression. The finding that FT4 concentrations after mirtazapine treatment were lower than baseline is in line with previous studies. Gendall et al. (45) found that in patients with MD treated with fluoxetine and nortriptyline, FT4 levels decreased significantly in responders, but not in non-responders. Joffe et al. (46) evaluated the effect of tricyclic antidepressant treatment on basal thyroid hormone levels in 28 subjects with primary MD and found that tricyclic antidepressant treatment was associated with significant reductions in measures ofFT4. Another study by Joffe et al. (47) examined changes in patients' thyroid hormone levels during a period of cognitive behaviour therapy and found significant decreases in measures of T4 in responders to cognitive behaviour therapy and increases in non-responders. Furthermore, Hoflich et al. (48) reported a decrease in T4 concentrations after treatment with fluvoxamine and maprotiline in 41 patients. The data can be interpreted taking into consideration that T4 levels may be elevated during episodes of acute depression. In this case, the declines in T4 concentrations may reflect a normalization during recovery. In fact, we found that higher FT4 concentrations at baseline predicted higher HAM-D scores at endpoint and, after 6 months of treatment, lower FT4 concentrations were associated with a decrease in HAM-D scores.
Our hypothesis is that long-term treatment with mirtazapine may increase T3 levels and decrease T4 suggesting an involvement of the de-iodination process ofT4 into T3. Some studies have found that untreated depressed patients had a reduced conversion ofT4 into T3, which can be reversed by successful treatment, suggesting a possible impairment in de-iodination process. In addition, it is known that treatment with lithium, carbamazepine, desipramine, fluoxetine, tranylcypromine, and mianserin can increase de-iodination ofT4 into T3 in specific areas of rat brain, influencing 5'I-deiodinase (5'D-I), 5'11 deiodinase (5'D-II) and 5III-deiodinase (5D-III) isoenzymes (49) (50) .
Finally, in this study no significant changes in TSH levels between baseline and endpoint were found among the entire samples and responders/nonresponders. However, subclinical hypothyroidism (SCH), defined as an elevated basal TSH with normal circulating levels ofT3 and T4, has been reported to occur in patients with a variety of affective syndromes including MD (51). Chueire et al. (52) conducted a population-based study of 451 over 60year-old outpatients of a general University Hospital and found that Mood disturbances were frequent in the elderly with elevated serum TSH levels, but they do not differ in the primary hypothyroid and the nonthyroidal sick patients. Berlin et al. (53) suggested that serum TSH concentration in the upper 25th percentile of the normal reference range may be associated with characteristics of severe major depression. However, overt hypothyroidism is very rare among depressive patients (54) (55) and this evidence is confirmed by our study. 
